

Early bone loss following menopause in hyperthyroidism.

Toshiya Hasegawa*

Department of Neurology, Showa University School of Medicine, Japan

Introduction

Hyperthyroidism is a medical condition characterized by the overproduction of thyroid hormones by the thyroid gland. The thyroid gland, a butterfly-shaped organ located in the front of the neck, plays a crucial role in regulating the body's metabolism through the production of hormones, primarily Thyroxin (T4) and Triiodothyronine (T3). When the thyroid gland becomes overactive, it releases an excessive amount of these hormones, leading to a range of symptoms and potential complications [1, 2].

Menopause is a natural physiological process marking the end of a woman's reproductive years, characterized by a decline in estrogen levels. Concurrently, hyperthyroidism, a condition involving overactive thyroid function, can also influence bone health. The interplay between menopause and hyperthyroidism has been recognized as a potential contributor to early bone loss in women. This article explores the intricate relationship between these two factors and their impact on bone health [3, 4].

Menopause typically occurs around the age of 50, leading to decreased estrogen production by the ovaries. Estrogen plays a crucial role in maintaining bone density by inhibiting the activity of osteoclasts, cells responsible for bone resorption. In hyperthyroidism, an excess of thyroid hormones accelerates metabolic processes, including bone turnover, potentially leading to increased bone loss. The decline in estrogen levels during menopause is a known risk factor for osteoporosis; a condition characterized by weakened bones and increased fracture risk. When hyperthyroidism coexists with menopause, the combination can exacerbate bone loss. Thyroid hormones influence bone remodeling by affecting osteoclast and osteoblast activity, disrupting the delicate balance required for optimal bone health [5, 6].

Hyperthyroidism is associated with elevated levels of thyroid hormones, which stimulate bone turnover. This increased activity leads to accelerated bone resorption, outpacing the formation of new bone tissue. Altered Calcium Homeostasis: Thyroid hormones affect calcium metabolism, a critical component of bone health. Elevated thyroid hormone levels can result in increased calcium loss from bones, further contributing to bone density reduction. Hormonal Imbalance Estrogen deficiency, a hallmark of menopause, and excess thyroid hormones create a hormonal imbalance that synergistically promotes bone loss. Estrogen's bone-

protective effects are compromised in the presence of thyroid hormone excess [7, 8].

Women approaching menopause with a history of hyperthyroidism should be closely monitored for bone health. Dual-Energy X-ray Absorptiometry (DEXA) scans can help assess bone density and identify early signs of osteoporosis. Hormone Replacement Therapy (HRT): Hormone replacement therapy, particularly estrogen replacement, may be considered in postmenopausal women with hyperthyroidism. However, the decision to use HRT should be made on an individual basis, weighing potential benefits against associated risks. Nutritional and Lifestyle Interventions. Adequate calcium and vitamin D intake, along with lifestyle modifications such as regular weight-bearing exercise, can contribute to maintaining bone health in women with hyperthyroidism post-menopause [9, 10].

Conclusion

The intersection of menopause and hyperthyroidism presents a complex scenario that can significantly impact bone health in women. Early bone loss, often a precursor to osteoporosis, is a concerning consequence of this interplay. Recognizing the potential risks and adopting proactive measures, including close monitoring, hormonal interventions, and lifestyle adjustments, is crucial in mitigating the adverse effects on bone density. Further research is needed to deepen our understanding of these interactions and develop targeted interventions for women navigating the challenges of both menopause and hyperthyroidism.

Reference

1. Kim SM, Ryu V, Miyashita S, et al. Thyrotropin, hyperthyroidism, and bone mass. *J Clin Endocrinol Metab.* 2021;106(12):4809-21.
2. Diamond T, Vine J, Smart R, et al. Thyrotoxic bone disease in women: a potentially reversible disorder. *Ann Intern Med.* 1994;120(1):8-11.
3. Durieux S, Mercadal L, Orcel P, et al. Bone mineral density and fracture prevalence in long-term kidney graft recipients. *Transplantation.* 2002 Aug 27;74(4):496-500.
4. Nguyen KD, Bagheri B, Bagheri H. Drug-induced bone loss: a major safety concern in Europe. *Expert Opin Drug Saf.* 2018;17(10):1005-14.

*Correspondence: Toshiya Hasegawa, Department of Neurology, Showa University School of Medicine, Japan, E-mail: toshiya@hasega.wa.jp

Received: 29-Nov-2023, Manuscript No. AAAGIM-23-122737; Editor assigned: 04-Dec-2023, PreQC No. AAAGIM-23-122737(PQ); Reviewed: 19-Dec-2023, QC No. AAAGIM-23-122737; Revised: 22-Dec-2023, Manuscript No. AAAGIM-23-122737(R); Published: 29-Dec-2023, DOI:10.35841/aaagim-7.6.204

5. Oliveira de Souza JG, Lopes Pereira Neto AR, Schuldt Filho G, et al. Impact of local and systemic factors on additional peri-implant bone loss. *Quintessence Int.* 2013;44(5).
6. Mohammadi B, Haghpanah V, Tavangar SM, et al. Modeling the effect of levothyroxine therapy on bone mass density in postmenopausal women: a different approach leads to new inference. *Theor Biol Med Model.* 2007;4:1-1.
7. Nilsson AG, Sundh D, Bäckhed F, et al. *Lactobacillus reuteri* reduces bone loss in older women with low bone mineral density: a randomized, placebo-controlled, double-blind, clinical trial. *Journal of internal medicine.* 2018 Sep;284(3):307-17.
8. Langdahl BL, Loft AG, Eriksen EF, et al. Bone mass, bone turnover, body composition, and calcium homeostasis in former hyperthyroid patients treated by combined medical therapy. *Thyroid.* 1996;6(3):161-8.
9. Zaidi M, Iqbal J, Blair HC, et al. Paradigm shift in the pathophysiology of postmenopausal and thyrotoxic osteoporosis. *Mt Sinai J Med.* 2009;76(5):474-83.
10. Deng T, Zhang W, Zhang Y, et al. Thyroid-stimulating hormone decreases the risk of osteoporosis by regulating osteoblast proliferation and differentiation. *BMC Endocr Disord.* 2021;21(1):1-0.

Citation: Hasegawa T. Early bone loss following menopause in hyperthyroidism. *Arch Gen Intern Med.* 2023;7(6):204